Amgen Seeks Speedy Ruling Against Colorado Drug Pricing Board

Drugmaker Amgen Inc. will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for the autoimmune treatment Enbrel, the company argued in a filing.

The Colorado Prescription Drug Affordability Board “can only benefit from knowing, as early as possible, whether and to what extent Colorado’s price-control scheme is preempted” by federal law, Amgen argued Monday in support of its motion for summary judgment in the US District Court for the District of Colorado.

The drugmaker argued in its March lawsuit that the Colorado law allowing the board to ...